Drug Trial Radar · NCT00095316
Caspofungin Study for Fungal Infections in Adults in Critical Care Settings
Last checked: Nov 20, 2026Latest source record: Dec 5, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,200
Planned (sponsor's estimate)
Start
Oct 2004
Primary completion
Not stated
Study completion Sep 2006
Sponsor
- Sponsor type
- NIH
- First posted
- Nov 3, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Adults admitted to intensive care units are at risk for a variety of complications. One of the most frequent complications is the development of new infections. Infections due to a fungus called Candida are of particular concern. This study will test the possibility that caspofungin, a new therapy for fungal infections, may reduce the rate of Candida infections in subjects at risk.
Conditions
- Candidiasis
Interventions
CaspofunginDrug
Caspofungin is an antifungal agent of the echinocandin class of glucan synthase inhibitor. Subjects receive Caspofungin acetate 50mg/day IV for 28 days.
PlaceboOther
Normal saline equivalent to that used to deliver the caspofungin given intravenously as a single daily dose infused over approximately 1 hour for 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama Hospital - Infectious Diseases
Birmingham, Alabama
University of Southern California - Infectious Diseases
Los Angeles, California
Harbor UCLA Medical Center - Medicine - Infectious Diseases
Torrance, California
University of Colorado Hospital - Denver
Denver, Colorado
MedStar Washington Hospital Center - Infectious Diseases
Washington D.C., District of Columbia
Jackson Memorial Hospital
Miami, Florida
Emory University School of Medicine - Infectious Diseases
Atlanta, Georgia
Rush University Medical Center
Chicago, Illinois
University of Illinois at Chicago College of Medicine - Infectious Diseases
Chicago, Illinois
The University of Chicago - Medicine - Infectious Diseases & Global Health
Chicago, Illinois
Loyola University - Emergency Facility
Maywood, Illinois
Infectious Disease of Indiana, PSC
Indianapolis, Indiana
University of Kentucky - UK Albert B Chandler Hospital
Lexington, Kentucky
Overton Brooks VA Medical Center
Shreveport, Louisiana
Mark Hatfield Clinical Research Center
Bethesda, Maryland
Tufts Medical Center - Infectious Diseases Clinic
Boston, Massachusetts
University of Michigan - VA Ann Arbor Health Care Systems
Ann Arbor, Michigan
Harper University Hospital
Detroit, Michigan
Henry Ford Health System - Henry Ford Hospital
Detroit, Michigan
University of Mississippi - Infectious Diseases
Jackson, Mississippi
Cooper University Hospital - Infectious Diseases
Camden, New Jersey
Duke University Medical Center - Duke Clinical Research Institute
Durham, North Carolina
Memorial Hermann Hospital
Houston, Texas
University of Texas Health Science Center at San Antonio - Infectious Diseases
San Antonio, Texas
University of Virginia Primary Health Center - Infectious Diseases and International Health
Charlottesville, Virginia
University of Wisconsin Hospital and Clinics - Clinical Science Center - Nephrology
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.